IRULYA THERAPEUTICS Beats Q3 EPS Expectations, Analysts Back BOS Trial Growth
IRULYA THERAPEUTICS Q3 2026 earnings beat—BOS trial spotlight shows promise for bone‑osteogenesis therapy, driving growth potential despite current losses.
2 minutes to read